Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Positron Emission Tomography (PET) for Alzheimer disease. Lansdale: HAYES, Inc. Directory Publication. 2017 Authors' conclusions Positron emission tomography (PET) is a 3-dimensional (3D) nuclear imaging technique that measures the level of physiologic and biochemical activity or other organic function in an organ or tissue by reflecting the distribution of a radiotracer that has been administered to the patient. PET has been proposed as a method for diagnosing and predicting development of Alzheimer disease (AD).
Relevant Questions: Is PET an accurate diagnostic test for detection or prediction of the development of AD? How does PET compare with other techniques?
What is the impact of PET on clinical management and health outcomes?
Are there any safety issues associated with the use of PET for detection or the prediction of AD development?
Have definitive patient selection criteria been established for PET imaging for AD? Indexing Status Subject indexing assigned by CRD MeSH Alzheimer Disease; Fluorodeoxyglucose F18; Humans; Positron-Emission Tomography Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32017000377 Date abstract record published 19/09/2017 |